Regulatory News
Thursday, July 21, 2016
BRIEF-Puma Biotech applies for marketing approval for breast cancer drug
* Submits NDA for PB272 (neratinib) to U.S. FDA for extended
adjuvant treatment of HER2-positive early stage breast cancer
Source text for Eikon:
Further company coverage:
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment